Morgan Stanley Freeline Therapeutics Holdings PLC Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.42 - $0.63 $798 - $1,197	-1,900 Reduced 0.99%	189,503 $87,000
Q4 2022 Feb 14, 2023	BUY	$0.46 - $0.73 $8,398 - $13,328	18,258 Added 10.54%	191,403 $91,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.1 $13,660 - $21,777	-19,798 Reduced 10.26%	173,145 $121,000
Q2 2022 Oct 27, 2022	BUY	$0.69 - $1.12 $5,666 - $9,198	8,213 Added 4.45%	192,943 $168,000
Q2 2022 Aug 15, 2022	BUY	$0.69 - $1.12 $5,666 - $9,198	8,213 Added 4.45%	192,943 $168,000
Q1 2022 Oct 27, 2022	SELL	$0.92 - $2.03 $7,555 - $16,672	-8,213 Reduced 4.26%	184,730 $207,000
Q1 2022 May 13, 2022	BUY	$0.92 - $2.03 $71,948 - $158,756	78,205 Added 73.41%	184,730 $207,000
Q4 2021 Feb 14, 2022	BUY	$1.97 - $3.45 $128,412 - $224,884	65,184 Added 157.67%	106,525 $211,000
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $125,676 - $367,934	41,341 New	41,341 $141,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.